BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31255253)

  • 1. Expression of micrornas in molecular genetic breast cancer subtypes.
    Kolesnikov NN; Veryaskina YA; Titov SE; Rodionov VV; Gening TP; Abakumova TV; Kometova VV; Torosyan MK; Zhimulev IF
    Cancer Treat Res Commun; 2019; 20():100026. PubMed ID: 31255253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
    Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
    J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
    Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
    J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
    PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
    Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
    Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.
    Cascione L; Gasparini P; Lovat F; Carasi S; Pulvirenti A; Ferro A; Alder H; He G; Vecchione A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2013; 8(2):e55910. PubMed ID: 23405235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
    Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
    Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical aspects of circulating miRNA-335 in breast cancer patients: A prospective study.
    Swellam M; Mahmoud MS; Hashim M; Hassan NM; Sobeih ME; Nageeb AM
    J Cell Biochem; 2019 Jun; 120(6):8975-8982. PubMed ID: 30506730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
    Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
    J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.
    Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy B; Raschioni C; Pusztai L; Calin GA; Santarpia L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters.
    Swellam M; El Magdoub HM; Hassan NM; Hefny MM; Sobeih ME
    Clin Biochem; 2018 Jun; 56():47-54. PubMed ID: 29679553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    Qattan A; Intabli H; Alkhayal W; Eltabache C; Tweigieri T; Amer SB
    BMC Cancer; 2017 Nov; 17(1):799. PubMed ID: 29183284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.